The table below shows ARROWHEAD PHARMACEUTICALS, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
$179.55M
-$462.85M
-$153.89M
-$136.13M
$171.31M
-$95.80M
Capital expenditure
$22.67M
$141.47M
$176.74M
$52.78M
$23.57M
$11.95M
Investing cash flow
-$129.29M
-$420.07M
-$96.16M
-$5.42M
-$141.68M
-$240.78M
Dividends paid
-
-
-
-
ARWR operating cash flow (10-K history)
ARROWHEAD PHARMACEUTICALS, INC. reported operating cash flow of $179.55M for fiscal year 2025. That is up 138.8% from -$462.85M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$64.43M (FY 2016) to $179.55M. Figures come from the company's audited annual reports as filed with the SEC.
